The GLP-1 Business Model Problem | Ep. 1. with Prof. Alex Miras скачать в хорошем качестве

The GLP-1 Business Model Problem | Ep. 1. with Prof. Alex Miras

Does the drug or the lifestyle intervention cause the weight loss? Why is the muscle loss panic probably wrong? And will oral GLP-1s cannibalise injectables — or create a funnel to them? Professor Alex Miras is a world-renowned obesity expert, clinical trialist, and consultant endocrinologist at Ulster University. In this conversation, he challenges some of the biggest assumptions in the GLP-1 market. ⏱️ CHAPTERS 0:00 Introduction & the oral GLP-1 boom 2:04 Do patients prefer pills or injections? 4:22 The fasting problem with oral tablets 5:23 Which patients should take orforglipron? 7:01 "Price will determine everything" 8:42 What are super responders? 10:15 What price point unlocks mass adoption in Europe? 11:43 Injectables vs orals: the 60/40 split 14:01 Tolerability — the big differentiator 17:07 Why real-world side effects are worse than trials 21:22 Which drug keeps patients on therapy longest? 24:03 Weight regain: why you can't just stop 26:21 The set point theory explained 29:10 ATTAIN-MAINTAIN trial: what it really proved 34:15 Muscle loss is probably a measurement problem 38:15 Anti-myostatin drugs: solution to a non-problem? 39:40 Is weight cycling dangerous? 43:28 Tapering programs are "hocus pocus" 44:37 Nutrition: what the drug changes and what it doesn't 46:50 The drug does 90% of the work — not lifestyle 49:25 NHS rationing & the 12-year rollout plan 53:46 GLP-1 effects beyond weight loss 56:02 Next-gen drugs: amylin & the pipeline 58:36 MariTide — the most fascinating molecule in obesity 1:00:11 The future: depot injections & gene therapy 1:03:34 Food noise: the huge mistake clinicians are making 1:08:16 Closing thoughts 🔔 Subscribe for more conversations with top researchers, clinicians, and industry experts on GLP-1s and obesity medicine. #GLP1 #Ozempic #Wegovy #Mounjaro #tirzepatide #semaglutide #orforglipron #obesity #weightloss #podcast #pharma #digitalhealth